On 13 April 2025, our third site investigator meeting convened 16 representatives from 11 sites across five countries, along with […]
Author: id.DRIVE consortium
Launch of the id.DRIVE respiratory syncytial virus (RSV) vaccine effectiveness study with the first site activation on 29 August 2024.
Universitätsklinikum Frankfurt in Germany was the first study site to be activated for the RSV vaccine effectiveness study in adults […]
Second in-person Site Investigator meeting
On 28 April 2024, the second in-person Study Contributor (Site) Investigator meeting took place as a satellite meeting during the […]
Poster presentation during ESCMID Global 2024
During the 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) held in Barcelona, Spain on […]
id.DRIVE welcomes 3 new members to its Independent Scientific Committee
With id.DRIVE´s expansion of scope beyond COVID-19 and broadened studies’ portfolio, we recently extended the breadth of expertise and number […]
id.DRIVE has activated a new Study Contributor (study site) in Italy
id.DRIVE has activated Luigi Sacco Hospital on February 28th, 2024. Luigi Sacco Hospital is located in north Milan, Italy, and […]
COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases.
id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who […]